logo

For the Inventor, By the Inventor

Munich, Germany

Stefan Weiss

This inventor holds 6 USPTO granted patents. Top assignees: Eberhard-Karls-Universitat Tubingen Universitatsklinkum, Other. Active years: 1987-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stefan Weiss. Retrieved from https://idiyas.com/inventor/stefan-weiss-a4x3gn7u

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 195(Granted Patents)


Location History:

  • Trostberg, DE (1987)
  • Tübingen, DE (2001 - 2002)
  • 80799 München, DE (2002)
  • München D-80799, DE (2002)
  • 80796 Munich, DE (2008)

Company Filing History:

goldMedal1 out of 1 
 
Eberhard-Karls-Universitat Tubingen Universitatsklinkum
 patent
silverMedal5 out of 834,513 
Other
 patents

Years Active: 1987-2008

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7371833 - [object Object] (2008-05-13),
2. 6451541 - Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc (2002-09-17),
3. 6426409 - Nucleic acid molecules that bind prion proteins and processes for the production thereof (2002-07-30),
4. 6347250 - Optically controllable microelectrode array for stimulating cells within a tissue (2002-02-12),
5. 6298270 - Retina implant (2001-10-02),
6. 4714602 - Process for the preparation of solid sodium hydrogen cyanamide (1987-12-22),

Title: The Innovative Contributions of Stefan Weiss

Introduction

Stefan Weiss is a prominent inventor based in Munich, Germany, known for his significant contributions to the field of molecular biology. With a total of six patents to his name, Weiss has made strides in the detection and treatment of transmissible spongiform encephalopathies.

Latest Patents

One of his latest patents involves a method for isolating nucleic acid molecules that can specifically interact with native prion proteins (PrP) and differentiate between native PrP and its isoforms. This inventive method includes steps such as incubating a pool of nucleic acids with purified PrP preparations, selecting and isolating the resulting protein/nucleic acid complexes, and optionally amplifying the specific nucleic acids. Additionally, the invention relates to the nucleic acid molecule produced by this method and its use in diagnosing and treating transmissible spongiform encephalopathies. Another notable patent focuses on chaperones capable of binding to prion proteins and distinguishing between the isoforms PrPc and PrPsc. This invention provides methods for the detection or isolation of prion proteins and offers a method for in vitro diagnosis of transmissible spongiform encephalopathy, along with pharmaceutical compositions for prevention or treatment.

Career Highlights

Throughout his career, Stefan Weiss has worked at various esteemed institutions, including Eberhard Karls University of Tübingen and its associated University Hospital. His work has significantly impacted the understanding and treatment of prion-related diseases.

Collaborations

Stefan Weiss has collaborated with notable colleagues such as Wilfried Nisch and Martin Stelzle, contributing to advancements in his field through shared expertise and innovative research.

Conclusion

Stefan Weiss's innovative work in the field of molecular biology, particularly regarding prion proteins, showcases his dedication to advancing medical science. His patents reflect a commitment to improving diagnostic and therapeutic methods for serious diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…